KR100331046B1 - 쇼그렌증후군치료제 - Google Patents

쇼그렌증후군치료제 Download PDF

Info

Publication number
KR100331046B1
KR100331046B1 KR1019930012594A KR930012594A KR100331046B1 KR 100331046 B1 KR100331046 B1 KR 100331046B1 KR 1019930012594 A KR1019930012594 A KR 1019930012594A KR 930012594 A KR930012594 A KR 930012594A KR 100331046 B1 KR100331046 B1 KR 100331046B1
Authority
KR
South Korea
Prior art keywords
syndrome
formula
quinuclidin
represented
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019930012594A
Other languages
English (en)
Korean (ko)
Other versions
KR940005274A (ko
Inventor
아베노부아끼
다께시다야스요시
Original Assignee
다이이치세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16540522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100331046(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다이이치세이야꾸 가부시끼가이샤 filed Critical 다이이치세이야꾸 가부시끼가이샤
Publication of KR940005274A publication Critical patent/KR940005274A/ko
Application granted granted Critical
Publication of KR100331046B1 publication Critical patent/KR100331046B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019930012594A 1992-07-10 1993-07-06 쇼그렌증후군치료제 Expired - Lifetime KR100331046B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4207485A JP2683783B2 (ja) 1992-07-10 1992-07-10 シェーグレン症候群治療剤
JP92-207485 1992-07-10

Publications (2)

Publication Number Publication Date
KR940005274A KR940005274A (ko) 1994-03-21
KR100331046B1 true KR100331046B1 (ko) 2002-08-19

Family

ID=16540522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930012594A Expired - Lifetime KR100331046B1 (ko) 1992-07-10 1993-07-06 쇼그렌증후군치료제

Country Status (15)

Country Link
US (1) US5340821A (enExample)
EP (1) EP0578511B1 (enExample)
JP (1) JP2683783B2 (enExample)
KR (1) KR100331046B1 (enExample)
AT (1) ATE184483T1 (enExample)
AU (1) AU666734B2 (enExample)
CA (1) CA2099970C (enExample)
DE (1) DE69326395T2 (enExample)
DK (1) DK0578511T3 (enExample)
ES (1) ES2138613T3 (enExample)
IL (1) IL106218A (enExample)
NO (1) NO303765B1 (enExample)
NZ (1) NZ248099A (enExample)
TW (1) TW230750B (enExample)
ZA (1) ZA934883B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
JPWO2006038596A1 (ja) * 2004-10-05 2008-05-15 アステラス製薬株式会社 涙液及び唾液乾燥症治療用医薬組成物
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) * 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8143400B2 (en) * 2008-01-10 2012-03-27 Apotex Pharmachem Inc. Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102711752B (zh) 2009-11-12 2014-06-18 阿卡西亚制药有限公司 氨甲酰甲胆碱用于治疗口干燥症的用途
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
CN102846607A (zh) * 2012-04-09 2013-01-02 珠海亿邦制药股份有限公司 一种以盐酸西维美林为活性成分的固体制剂及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314444A2 (en) * 1987-10-28 1989-05-03 State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001396A (en) * 1971-08-04 1977-01-04 Chinoin Pharmaceutical And Chemical Works Ltd. Hormonal product extracted from parathyroid gland and process for the preparation thereof
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4684727A (en) * 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
ZA868369B (en) * 1986-01-10 1987-11-25 Israel State Derivatives of quinuclidine
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
CA1303503C (en) * 1987-11-10 1992-06-16 Marc Plamondon Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
US5242930A (en) * 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314444A2 (en) * 1987-10-28 1989-05-03 State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments

Also Published As

Publication number Publication date
US5340821A (en) 1994-08-23
JPH0624981A (ja) 1994-02-01
DK0578511T3 (da) 2000-04-03
IL106218A (en) 1997-02-18
KR940005274A (ko) 1994-03-21
AU4181993A (en) 1994-01-13
DE69326395T2 (de) 2000-04-20
NZ248099A (en) 1999-07-29
EP0578511A1 (en) 1994-01-12
IL106218A0 (en) 1993-11-15
ES2138613T3 (es) 2000-01-16
ATE184483T1 (de) 1999-10-15
CA2099970A1 (en) 1994-01-11
ZA934883B (en) 1994-02-03
NO932520D0 (no) 1993-07-09
JP2683783B2 (ja) 1997-12-03
CA2099970C (en) 2003-12-30
AU666734B2 (en) 1996-02-22
DE69326395D1 (de) 1999-10-21
NO932520L (no) 1994-01-11
TW230750B (enExample) 1994-09-21
NO303765B1 (no) 1998-08-31
EP0578511B1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
KR100331046B1 (ko) 쇼그렌증후군치료제
US5580880A (en) Method for the treatment of xerostomia
HU225887B1 (en) Process for producing pharmaceutical compositions containing flurbiprofen having painkiller activity
JPS6253932A (ja) 血管拡張および抗無酸素症剤
US4814353A (en) Therapeutic and prophylactic agent for gastritis
US4419345A (en) Sleep-inducing pharmaceutical composition and method
US6410557B2 (en) Dry skin remedies
WO1990011080A1 (en) Drug for improving brain function
US3462534A (en) Production of an antidepressant effect with esters of gallic acid
EP2146713B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
DE3781339T2 (de) Therapeutisches mittel fuer gastritis.
JP2817334B2 (ja) 神経細胞保護剤
US3749781A (en) Pharmaceutical composition and method of treatment
IL37889A (en) Indulamin inhibitors - N - methyl transferase
JP3654939B2 (ja) ドライバジャイナ治療剤
CS209859B2 (cs) Způsob výroby nových derivátů aminokyselin

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930706

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980423

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19930706

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000214

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20001030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20000214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20001130

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20001030

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20011231

Appeal identifier: 2000101002837

Request date: 20001130

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20001130

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20001130

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20000410

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010221

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20011231

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20010129

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20020130

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20020320

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20020320

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20041223

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20060131

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20070205

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20080214

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20090311

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20100310

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20110223

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20120223

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20130227

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140106

Termination category: Expiration of duration